Utilities -
Regulated Water - NYSE - BR
$ 19.75
-2.13 %
$ 13.5 B
Market Cap
7.68
P/E
1. INTRINSIC VALUE
Balance Sheet
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
| Current Assets | 10.6 B |
| Cash & Short-Term Investments | 5.38 B |
| Receivables | 5.01 B |
| Other Current Assets | 212 M |
| Non-Current Assets | 70.4 B |
| Long-Term Investments | 18.6 B |
| PP&E | 686 M |
| Other Non-Current Assets | 51.1 B |
| Current Liabilities | 12 B |
| Accounts Payable | 767 M |
| Short-Term Debt | 3.13 B |
| Other Current Liabilities | 8.07 B |
| Non-Current Liabilities | 32.1 B |
| Long-Term Debt | 22.1 B |
| Other Non-Current Liabilities | 9.94 B |
EFFICIENCY
Earnings Waterfall
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
| Revenue | 36.1 B |
| Cost Of Revenue | 16.6 B |
| Gross Profit | 19.5 B |
| Operating Expenses | 4.03 B |
| Operating Income | 15.5 B |
| Other Expenses | 1.87 B |
| Net Income | 13.6 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
| Net Income | 13.6 B |
| Depreciation & Amortization | 2.68 B |
| Capital Expenditures | -101 M |
| Stock-Based Compensation | 0 |
| Change in Working Capital | -1.07 B |
| Others | -7.69 B |
| Free Cash Flow | 7.3 B |
Wall Street Analysts Price Targets
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
Wall Street analysts predict an average 1-year price target for SBS of $24.5 , with forecasts ranging from
a
low of
$24.5 to a high of $24.5 .
SBS Lowest Price Target
Wall Street Target
24.5 USD
24.05%
SBS Average Price Target
Wall Street Target
24.5 USD
24.05%
SBS Highest Price Target
Wall Street Target
24.5 USD
24.05%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.636 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
SBS ANNOUNCES GROUNDBREAKING PARTNERSHIP WITH THE ROKU CHANNEL FOR LIVESTREAMING THE NEW LAMUSICA TV
Premier Latino Audiovisual Entertainment Destination to Reach Millions of Spanish-Speaking Viewers MIAMI , June 9, 2025 /PRNewswire/ -- Spanish Broadcasting System, Inc. (SBS), the largest Hispanic-controlled media and entertainment company in the United States, today announced that LaMusica, its top-ranked audiovisual entertainment app, will begin livestreaming as LaMusica TV on The Roku Channel. This summer, millions of Roku's Hispanic customers in the U.S. and Mexico will gain access to LaMusica TV via The Roku Channel, the #2 app on the Roku platform in the U.S. by engagement.
prnewswire.com
- 1 month ago
Spanish Broadcasting System Sells Puerto Rico TV to Christian Media Group
SAN JUAN, Puerto Rico , June 5, 2025 /PRNewswire/ -- Spanish Broadcasting System, Inc. (SBS), the largest minority-owned Hispanic media company in the U.S., has entered into an Asset Purchase Agreement for the sale of WVEO(DT), WTCV(DT), and WVOZ-TV Puerto Rico to Word of God Fellowship, Inc., a Christian faith-based broadcast owner-operator known as Daystar Television Network. This strategic sale reinforces SBS's focus on its core audio and digital businesses, continuing SBS's industry-leading radio portfolio dominance (including the most-listened-to-and-streamed station in the nation, WSKQ-FM, in New York City), along with its digital platforms (among which is included the highest-rated Latino music streaming app, LaMusica) in further serving and empowering Hispanic audiences across the US and Puerto Rico footprints.
prnewswire.com
- 1 month ago
Sabesp: The Brazilian Utilities Stock Your Portfolio Desperately Needs
SABESP operates in a rapidly developing market that offers substantial long-term growth opportunities. Its expanding customer base and increasing water demand support steady revenue expansion. The ongoing privatization process is unlocking significant value by improving operational efficiency and attracting strategic investments. This transition enhances both governance and growth prospects. SABESP's disciplined capital expenditure strategy is building a strong and sustainable competitive moat. Focused investments in infrastructure improve service quality and create high barriers to entry.
seekingalpha.com
- 1 month ago
4 Stocks to Watch From the Thriving Water Supply Industry
Water utilities like AWK, SBS, MSEX and ARTNA are likely to benefit from stable demand for water and wastewater services. Capital-intensive utilities are set to gain from interest rate cuts.
zacks.com
- 1 month ago
4 Top-Ranked Efficient Stocks to Buy for Solid Gains Amid Volatility
Invest in stocks of MVST, SBS, CARG and ATR to tap their high-efficiency levels.
zacks.com
- 2 months ago
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (SBS) Q1 2025 Earnings Call Transcript
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (NYSE:SBS ) Q1 2025 Results Conference Call May 13, 2025 7:00 AM ET Company Participants Daniel Szlak - Chief Financial Officer and Investor Relations Officer Carlos Piani - Chief Executive Officer Conference Call Participants Guilherme Lima - Santander Joao Pimentel - Citibank Maria Carolina - Safra Bruno Amorim - Goldman Sachs Luiza Candiota - Itau Francisco Navarrete - Banco Antonio Junqueira - BTG Pactual Andre Sampaio - Banco Santander Operator Good morning, and welcome to SABESP First Quarter of 2025 Earnings Presentation. With us here today are Carlos Piani, CEO; Daniel Szlak, CFO; and Thiago Levy, Investor Relations.
seekingalpha.com
- 2 months ago
What Makes Sabesp (SBS) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
zacks.com
- 2 months ago
Here's Why 'Trend' Investors Would Love Betting on Sabesp (SBS)
If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
zacks.com
- 2 months ago
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients
Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI Congress ; Click here to register There are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management including total parenteral nutrition (TPN) - which carries the risk of morbidity, infections, metabolic complications, liver and kidney problems, and neurodevelopmental delay This proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) PRIME program for expediated and assisted regulatory approval in the EU as well as FDA's Breakthrough Therapies program for expedited regulatory approval in the US SAN FRANCISCO, CA / ACCESS Newswire / April 30, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced initial proof-of-concept results showing that a novel liquid formulation of crofelemer reduced the required TPN and/or supplementary intravenous fluids, collectively referred to as parenteral support (PS) in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) by up to 27% and 12.5% respectively. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output - an indicator of improved nutrient oral absorption.
accessnewswire.com
- 2 months ago
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management This data was presented at the Annual ELITE PED-GI Congress by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today issued a reminder that Jaguar is hosting an investor webcast on Wednesday, April 30, 2025 at 8:30 AM Eastern to review the initial results of the proof-of-concept investigator-initiated trial of a novel liquid formulation of crofelemer, Jaguar's plant-based anti-secretory prescription drug, in patients with the rare diseases microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) that were presented by Dr. Mohamad Miqdady on April 26, 2025 at the 11th Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates. Participation Instructions for Jaguar Investor Webcast When: Wednesday, April 30, 2025 at 8:30 AM Eastern Time Where: Online Registration link for conference: Click Here About Crofelemer Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest.
accessnewswire.com
- 2 months ago
Sabesp: Market's Just Starting To Price The New Playbook
SABESP is just beginning to unlock the benefits of privatization, with a bold R$70 billion investment plan through 2030 aimed at full sanitation coverage. Despite macro headwinds in Brazil, SBS ADRs have outperformed, buoyed by privatization momentum and significant operational upside. The stock still trades at an attractive EV/RAB of 1.22x, not fully reflecting future execution or asset base growth.
seekingalpha.com
- 3 months ago
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management Proof-of-concept data in MVID from this study would provide support for crofelemer's potential inclusion in the EMA's PRIME program for novel medicines targeting unmet medical needs and the FDA's Breakthrough Therapies program SAN FRANCISCO, CA / ACCESS Newswire / April 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that preliminary results from the ongoing pediatric investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for various congenital diarrheal disorders (CDD), including MVID and SBS with intestinal failure (SBS-IF), will be presented by Dr. Mohamad Miqdady at the April 24-26, 2025 Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates. MVID and SBS-IF, rare orphan diseases requiring intensive parenteral nutrition and support, have severe morbidity and mortality implications and impact the quality of life of both patients and their caregivers.
accessnewswire.com
- 3 months ago
8. Profile
Summary
Companhia de Saneamento Básico do Estado de São Paulo - SABESP SBS
COUNTRY
BR
INDUSTRY
Regulated Water
MARKET CAP
$ 13.5 B
Dividend Yield
0.00%
Description
Companhia de Saneamento Básico do Estado de São Paulo SABESP provides water and sewage services to residential, commercial, industrial, and governmental customers. It provides water supply, sanitary sewage, urban rainwater management and drainage, urban cleaning, and solid waste management services, as well as related activities, including the planning, operation, maintenance, and commercialization of energy. As of December 31, 2021, the company provided water services through 9.8 million water connections to approximately 27.8 million people; sewage services through 8.4 million sewage connections to approximately 24.6 million people; and operated 88,904 kilometers of water pipes and water transmission lines, as well as 61,122 kilometers of sewer lines. It also offers water and/or sewage services to four other municipalities through special purpose companies. The company was founded in 1954 and is headquartered in São Paulo, Brazil.
Contact
Rua Costa Carvalho, 300, São Paulo, SP, 05429-900
https://www.sabesp.com.br
IPO
Date
May 10, 2002
Employees
10552
Officers
Mr. Gustavo do Valle Fehlberg
Chief of Corporate Services Officer & Member of Executive Board
Ms. Samanta I. Salvador Tavares de Souza
Chief Corporate Affairs & Sustainability Officer and Member of Executive Board
Mr. Daniel Szlak
Chief Financial Officer, Investor Relations Officer & Member of Executive Board
Mr. Roberval Tavares de Souza
Chief Engineering Officer & Member of Executive Board
Joshua Bressane Jr.
Chief People Officer & Performance Officer and Member of Executive Board
Mr. Carlos Augusto Leone Piani C.F.A.
Chief Executive Officer & Member of Executive Board
Mr. Rafael Costa Strauch
Chief Corporate Development Officer & Member of Executive Board
Ms. Debora Pierini Longo
Chief Operations & Maintenance Officer and Member of Executive Board
Ms. Maria Alicia Lima Peralta
Chief Legal Officer & Member of Executive Board
Ms. Luciane Godinho Domingues
Chief Regulation & Power Procurement Officer and Member of Executive Board